January 3, 2018 / 2:03 PM / in 14 minutes BRIEF-Spark Therapeutics Announces Programs To Improve Patient Access To LUXTURNA Reuters Staff 1 Min Read 
Jan 3 (Reuters) - Spark Therapeutics Inc: 
* SPARK THERAPEUTICS ANNOUNCES FIRST-OF-THEIR-KIND PROGRAMS TO IMPROVE PATIENT ACCESS TO LUXTURNAâ„¢ (VORETIGENE NEPARVOVEC-RZYL), A ONE-TIME GENE THERAPY TREATMENT 
* SPARK THERAPEUTICS INC - ALSO HAS REACHED AN AGREEMENT IN PRINCIPLE WITH AFFILIATES OF EXPRESS SCRIPTS TO ENABLE INNOVATIVE CONTRACTING MODEL 
* SPARK THERAPEUTICS INC - IN ACTIVE DISCUSSIONS WITH OTHER COMMERCIAL INSURERS REGARDING THE OFFERING 
* SPARK THERAPEUTICS- REACHED DEAL WITH HARVARD PILGRIM TO MAKE LUXTURNA AVAILABLE UNDER OUTCOMES-BASED REBATE ARRANGEMENT & INNOVATIVE CONTRACTING MODEL Source text for Eikon: Further company coverage: